Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

Conditions:   Embryonal Rhabdomyosarcoma;   Fusion-Negative Alveolar Rhabdomyosarcoma Interventions:   Drug: Cyclophosphamide;   Biological: Dactinomycin;   Radiation: Radiation Therapy;   Drug: Vincristine Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials